JAK1 and head and neck squamous cell carcinoma: Similarly, for advanced solid cancers, including HNSCC, an active phase 1b trial combines pembrolizumab (anti-PD1) with the JAK1 inhibitor itacitinib (INCB039110) (ClinicalTrials.gov #NCT02646748) (Table 1; Figure 2A).